Contact
searchSearch
HMP Global
Login

News

Elias Jabbour, MD
Conference Coverage
Utilizing Immunotherapies for Optimal Treatment of Ph-Positive Acute Lymphoblastic Leukemia
06/29/2025
Elias Jabbour, MD
At the 2025 Great Debates in Hematologic Malignancies meeting, Elias Jabbour, MD, participated in a debate on the optimal regimen for treating Ph-positive ALL, highlighting the benefits of utilizing immunotherapies.
At the 2025 Great Debates in Hematologic Malignancies meeting, Elias Jabbour, MD, participated in a debate on the optimal regimen for treating Ph-positive ALL, highlighting the benefits of utilizing immunotherapies.
At the 2025 Great Debates in...
06/29/2025
Oncology
Shira Dinner, MD
Conference Coverage
Benefits of Chemotherapy Plus Allogeneic Stem Cell Transplantation as Treatment Strategy for Ph-Positive ALL
06/28/2025
Shira Dinner, MD
Shira Dinner, MD, debates the benefits of chemotherapy followed by allogeneic stem cell transplantation among patients with Philadelphia chromosome-positive acute lymphoblastic leukemia at the 2025 Great Debates in Hematologic Malignancies.
Shira Dinner, MD, debates the benefits of chemotherapy followed by allogeneic stem cell transplantation among patients with Philadelphia chromosome-positive acute lymphoblastic leukemia at the 2025 Great Debates in Hematologic Malignancies.
Shira Dinner, MD, debates the...
06/28/2025
Oncology
News
Autologous Hematopoietic Stem Cell Transplant Shows Safety for Late Treatment Intensification for Ph-Negative ALL
05/16/2025
Emily Estrada
Autologous hematopoietic stem cell transplantation demonstrated relative safety for patients with Philadelphia chromosome-negative acute lymphoblastic leukemia, according to a recent study.
Autologous hematopoietic stem cell transplantation demonstrated relative safety for patients with Philadelphia chromosome-negative acute lymphoblastic leukemia, according to a recent study.
Autologous hematopoietic stem...
05/16/2025
Oncology
News
Dasatinib Plus CAR T-Cell Therapy Shows Encouraging Efficacy for Patients With Newly Diagnosed Ph-Positive ALL
04/29/2025
Emily Estrada
For patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia, dasatinib plus sequential CD19-CD22 CAR T-cell therapy demonstrated improved outcomes and high rates of complete molecular remission.
For patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia, dasatinib plus sequential CD19-CD22 CAR T-cell therapy demonstrated improved outcomes and high rates of complete molecular remission.
For patients with newly...
04/29/2025
Oncology
News
Inaticabtagene Autoleucel Demonstrates Efficacy and Tolerability for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
03/25/2025
Emily Estrada
Inaticabtagene autoleucel treatment for patients with relapsed/refractory B-cell acute lymphoblastic leukemia showed efficacy and durability in a phase 2 clinical trial.
Inaticabtagene autoleucel treatment for patients with relapsed/refractory B-cell acute lymphoblastic leukemia showed efficacy and durability in a phase 2 clinical trial.
Inaticabtagene autoleucel...
03/25/2025
Oncology
News
Durability and Tolerability of Obecabtagene Autoleucel CAR-T Therapy for R/R B-Cell Acute Lymphoblastic Leukemia
02/07/2025
Emily Estrada
For patients with relapsed/refractory B-cell acute lymphoblastic leukemia, obecabtagene autoleucel anti-CD19 CAR-T therapy showed promising durability and tolerability, according to a recent study.
For patients with relapsed/refractory B-cell acute lymphoblastic leukemia, obecabtagene autoleucel anti-CD19 CAR-T therapy showed promising durability and tolerability, according to a recent study.
For patients with...
02/07/2025
Oncology
News
FDA Approves Oral Formulation of Imatinib for Patients With Certain Leukemias and Gastrointestinal Tumors
11/25/2024
Stephanie Holland
The FDA has approved an advanced liquid formulation of imatinib for patients with certain leukemias and gastrointestinal tumors to increase dosing accuracy.
The FDA has approved an advanced liquid formulation of imatinib for patients with certain leukemias and gastrointestinal tumors to increase dosing accuracy.
The FDA has approved an advanced...
11/25/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Blinatumomab Added to Consolidation Chemotherapy Improves Overall Survival Among Patients in MRD-Negative Remission From B-Cell Precursor ALL
08/14/2024
Amber Denham
According to a phase 3 study, the addition of blinatumomab to consolidation chemotherapy for adult patients in measurable residual disease-negative remission from B-cell precursor acute lymphoblastic leukemia significantly improved overall...
According to a phase 3 study, the addition of blinatumomab to consolidation chemotherapy for adult patients in measurable residual disease-negative remission from B-cell precursor acute lymphoblastic leukemia significantly improved overall...
According to a phase 3 study,...
08/14/2024
Oncology
News
FDA Grants Approval to Blinatumomab Consolidation Therapy for CD19-Positive Philadelphia Chromosome-Negative B-cell Precursor ALL
06/21/2024
The FDA granted approval to blinatumomab for adult and pediatric patients with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multi-phase chemotherapy.
The FDA granted approval to blinatumomab for adult and pediatric patients with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multi-phase chemotherapy.
The FDA granted approval to...
06/21/2024
Oncology

Recent News

News
Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL
09/26/2025
Emily Estrada
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE...
09/26/2025
Oncology
News
PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL
09/26/2025
Emily Estrada
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large...
09/26/2025
Oncology
News
Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies
09/26/2025
Emily Estrada
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional...
09/26/2025
Oncology
FDA Approval
FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
09/25/2025
Stephanie Holland
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved...
09/25/2025
Oncology
News
Pexidartinib Shows Durable Response Among Patients with Tenosynovial Giant Cell Tumors
09/25/2025
Allison Casey
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained...
09/25/2025
Oncology
News
Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma
09/24/2025
Emily Estrada
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with...
09/24/2025
Oncology
News
First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer
09/23/2025
Stephanie Holland
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3...
09/23/2025
Oncology
News
Novel Anti-CSF1 Receptor Antibody for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial,...
09/23/2025
Oncology
News
Adverse Events With Pexidartinib for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the...
09/23/2025
Oncology
News
Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer
09/22/2025
Stephanie Holland
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the...
09/22/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use